scispace - formally typeset
M

Masaomi Kato

Researcher at Yale University

Publications -  18
Citations -  3018

Masaomi Kato is an academic researcher from Yale University. The author has contributed to research in topics: Caenorhabditis elegans & RNA. The author has an hindex of 14, co-authored 18 publications receiving 2792 citations. Previous affiliations of Masaomi Kato include Centenary Institute & National Institute of Genetics.

Papers
More filters
Journal ArticleDOI

Integrative analysis of the Caenorhabditis elegans genome by the modENCODE project

Mark Gerstein, +130 more
- 24 Dec 2010 - 
TL;DR: These studies identified regions of the nematode and fly genomes that show highly occupied targets (or HOT) regions where DNA was bound by more than 15 of the transcription factors analyzed and the expression of related genes were characterized, providing insights into the organization, structure, and function of the two genomes.
Journal ArticleDOI

Role of CG and Non-CG Methylation in Immobilization of Transposons in Arabidopsis

TL;DR: It is concluded that CG and non-CG methylation systems redundantly function for immobilization of transposons.
Journal ArticleDOI

Comparative analysis of the transcriptome across distant species

Mark Gerstein, +107 more
- 28 Aug 2014 - 
TL;DR: It is found in all three organisms that the gene-expression levels, both coding and non-coding, can be quantitatively predicted from chromatin features at the promoter using a ‘universal model’ based on a single set of organism-independent parameters.
Journal ArticleDOI

MicroRNAs Both Promote and Antagonize Longevity in C. elegans

TL;DR: In this paper, the authors show that multiple miRNAs change expression in C. elegans aging and that mutations in several of the most upregulated microRNAs lead to life-span defects.
Journal ArticleDOI

The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells.

TL;DR: It is confirmed that mir-34 is required for a normal cellular response to DNA damage in vivo resulting in altered cellular survival post-irradiation, and point to a potential therapeutic use for anti-miR-34 as a radiosensitizing agent in p53-mutant breast cancer.